Although HER2 has been undoubtedly proved a prognostic and predictive biomarker in human cancer, its clinical extrapolation is conditioned by the variability of reported HER2 alterations depending on the disease stage, the tested populations and both inter-tumor and intra-tumor heterogeneity. The gene discussed is ERBB2; the disease is neoplasm.